Title	Characterization of extensively drug-resistant Mycobacterium tuberculosis in Nepal
Author(s)	Poudel, Ajay; Maharjan, Bhagwan; Nakajima, Chie; Fukushima, Yukari; Pandey, Basu D.; Beneke, Antje; Suzuki, Yasuhiko
Citation	Tuberculosis, 93(1), 84-88 https://doi.org/10.1016/j.tube.2012.10.007
Issue Date	2013-01
Doc URL	http://hdl.handle.net/2115/52260
Type	article (author version)
File Information	Tub93-1_84-88.pdf

[Instructions for use](#)

Characterization of extensively drug-resistant *Mycobacterium tuberculosis* in Nepal

Ajay Poudel^a, Bhagwan Maharjan^b, Chie Nakajima^a, Yukari Fukushima^a, Basu D. Pandey^c, Antje Beneke^d, and Yasuhiko Suzuki^{a, e, *}

^aHokkaido University Research Center for Zoonosis Control, Sapporo, Japan

^bGerman Nepal Tuberculosis Project, Kathmandu, Nepal

^cSukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal

^dKuratorium Tuberculose in der welt e. v., Gauting, Germany

^eJST-JICA/SATREPS, Tokyo, Japan

A.P. and B.M. contributed equally to this work.

*Corresponding author

E-mail: suzuki@czc.hokudai.ac.jp

Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Kita 20-Nishi 10, Kita-ku. Sapporo 001-0020, Japan.

Phone: +81-11-706-9503, Fax: +81-11-706-7310

Running Head: Emergence of XDR-TB in Nepal

Summary

The emergence of extensively drug-resistant tuberculosis (XDR-TB) has raised public health concern for global control of TB. Although molecular characterization of drug resistance-associated mutations in multidrug-resistant isolates in Nepal has been made, mutations in XDR isolates and their genotypes have not been reported previously. In this study, we identified and characterized 13 XDR *Mycobacterium tuberculosis* isolates from clinical isolates in Nepal. The most prevalent mutations involved in rifampicin, isoniazid, ofloxacin, and kanamycin/capreomycin resistance were Ser531Leu in *rpoB* gene (92.3%), Ser315Thr in *katG* gene (92.3%), Asp94Gly in *gyrA* gene (53.9%) and A1400G in *rrs* gene (61.5%), respectively. Spoligotyping and multilocus sequence typing revealed that 69 % belonged to Beijing family, especially modern types. Further typing with 26-loci variable number of tandem repeats suggested the current spread of XDR *M. tuberculosis*. Our result highlights the need to reinforce the TB policy in Nepal with regard to control and detection strategies.

Key words: XDR, tuberculosis, Nepal

1. Introduction

Worldwide emergence of multi- and extensively drug-resistant tuberculosis (MDR and XDR-TB) has become a major obstacle to TB control. XDR-TB is a form of TB caused by *Mycobacterium tuberculosis* (MTB) strains, which is resistant to isoniazid (INH) and rifampicin (RIF), defined as multidrug-resistant MTB (MDR-MTB), as well as fluoroquinolone (FQ) and any of the second-line anti-TB injectable drugs, amikacin (AMK), kanamycin (KAN), or capreomycin (CAP). By the end of 2010, 68 countries had reported at least one case of XDR-TB.¹ XDR-TB is the result of an adverse treatment outcome of MDR-TB; many cases are never diagnosed due to limitations in laboratory capacity to test for second-line drug resistance.² Treatment of XDR-TB patients is more challenging and less successful than that of patients with other types of TB.³ An extremely high death rate from XDR-TB was reported in patients co-infected with HIV in South Africa.^{2,4}

In Nepal, TB is a major public health problem. The incidence of all forms of TB was estimated to be 173/100,000 population while the incidence of new smear-positive cases was at 77/100,000 in 2008. The four surveys conducted between 1996 and 2007 have indicated the fluctuating prevalence of MDR-TB among new cases of between 1.1% and 3.7% (1.1% in 1996, 3.7% in 1999, 1.4% in 2001 and 2.9% in 2007). The latest estimate of MDR-TB is 2.9% and 11.7% among new and recurrent cases, respectively.^{1,5,6} Although the prevalence of drug-resistance confirming mutations in MDR-TB isolates in Nepal have been reported recently,⁶ to the best of our knowledge, no published data on mutations and genotypes of XDR-MTB strains are currently available from Nepal.

Molecular epidemiological studies of *M. tuberculosis* strains have identified variability in the phylogeography of strains globally.^{7,8} Beijing strains are most prevalent globally and also associated with enhanced acquisition of drug resistance; however their resistance patterns varied regionally.⁹ Drug resistance in *M. tuberculosis* is commonly caused by mutations in various genes. Previous works have indicated that mutations within 81-bp core region of the RNA polymerase β -subunit gene (*rpoB*) gene are the cause of RIF resistance in more than 90% of cases.^{10,11} In contrast, several different loci are known to be involved in INH resistance, especially *katG* and *inhA*.^{6,10} Mutations in a conserved quinolone resistance-determining region (QRDR) of the *gyrA* or *gyrB* genes encoding DNA gyrase are often involved in fluoroquinolone (FQ) resistance.¹²

Resistance to aminoglycosides (KAN and AMK) and CAP is attributed to mutations in 16s rRNA (*rrs*) gene.^{13, 14}

The present study documents drug resistance-associated mutations in XDR isolates from Nepal. To gain an insight into the epidemiology of these isolates, genotyping by using spoligotyping, multilocus sequence typing (MLST) and variable number of tandem repeats (VNTR) were also performed.

2. Materials and methods

2.1. *M. tuberculosis* isolates

A total of 109 MDR *M. tuberculosis* clinical isolates were randomly selected from isolates bank at German Nepal Tuberculosis Project (GENETUP), Nepal, collected over a 3-year period from 2007 to 2010. Each isolates were recovered from individual patients with pulmonary TB.

2.2. Antibiotic susceptibility testing

Testing for susceptibility to first- and second-line drugs was carried out at GENETUP using the conventional proportional method on Löwenstein-Jensen medium according to the World Health Organization guidelines¹⁵ with the following critical drug concentrations: INH (Cat No. 2261/0801; Fatol Arzneimittel GmbH, Schiffweiler, Germany); 0.2 µg/ml, RIF (Cat No. 004030; Fatol); 40 µg/ml, STR (Cat No. S6501; Sigma-Aldrich, St. Louis, MO); 4 µg/ml, EMB (Cat No. 1237/0806; Fatol); 2 µg/ml, ofloxacin (OFX; Cat No. O8757; Sigma-Aldrich); 2 µg/ml, KAN (Cat No. 60615; Sigma-Aldrich); 30 µg/ml and CAP (Cat No. C4142; Sigma-Aldrich); 40 µg/ml.

2.3. DNA extraction

DNA was prepared for PCR by mechanical disruption, as described previously.⁶ Briefly, the colonies were suspended in TE buffer consisting of 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA in a 2 ml screw-cap vial, one-fourth of which was filled with 0.5 g glass beads (0.1 mm) (Bio Spec Products Inc., Bartlesville, OK). Mycobacterial cells were disrupted by shaking with 0.5 ml chloroform on a cell disrupter (Micro smash; Tomy Seiko Co. Ltd., Tokyo, Japan) for 1 min. After centrifugation, the DNA in the upper layer was concentrated by ethanol precipitation and dissolved in 100 µl TE buffer.

2.4. PCR amplification and DNA sequencing of drug resistance-associated genes

PCR reactions were performed in a 20 µl mixture consisted of 0.25 mM each of dNTPs, 0.5 M betaine, 0.5 µM of each primer (Primers for *rrs*, *gyrA* and *gyrB* in Table 1 and those in Poudel A et al.⁶ for *rpoB*, *katG* and *inhA* gene segment amplification). One U GoTaq DNA Polymerase (Promega, Madison, WI), GoTaq buffer and 1 µl DNA

template. The reactions were carried out in a thermal cycler (Bio-Rad Laboratories, Ipswich, MA) under the following conditions: initial denaturation at 96 °C for 60s followed by 35 cycles of denaturation at 96 °C for 10 s, annealing at 55° C for 10 s and extension at 72 °C for 30 s with a final extension at 72 °C for 5 min. PCR products were sequenced according to the manufacturer's instructions with the same primers used for PCR and the Big Dye Terminator v3.1 Cycle Sequencing Kit (Life Technologies Corp., Carlsbad, CA) using an ABI PRISM 3130xl Genetic Analyzer (Life Technologies Corp.). The resulting sequences were compared with wild-type sequences of *M. tuberculosis* H37Rv using Bio-Edit software (version 7.0.9) (<http://www.mbio.ncsu.edu/bioedit/bioedit.html>).

2.5. Phylogenetic markers

Spoligotyping was performed according to the standard protocol.¹⁶ and the spoligotype in the binary format was compared with the SpolDB4 database.¹⁷ Another molecular epidemiological investigation was performed by PCR amplification of the 26 variable *M. tuberculosis* microsatellites and assigned an allele number based on the number of repeats as described previously.¹⁸ A combined spoligotype-VNTR UPGMA3 dendrogram was computed and drawn using Bionumerics 6.0 version software (Applied Maths, Sint-Marten-Latems, Belgium). MLST targeting 10 chromosomal positions were performed according to Filliol *et al.*¹⁹

3. Results

3.1. Drug-susceptibility patterns

Among 109 MDR-MTB isolates obtained, 13 were found to be XDR (Table 2). Three of the patients having XDR-TBs (84, 90 and 123) were naive for MDR treatment. Of the remaining 96 isolates, 41, 1, and 1 were mono-resistant to OFX, KAN, and CAP, respectively, and categorized as pre-XDR-MTB.

3.2. Geographical distribution of XDR *M.tuberculosis* isolates

The XDR-MTB isolates were originated from patients living in five main cities of Nepal (Figure 1): Kathmandu (n = 7), Pokhara (n = 3), Butwal (n = 1), Bhairahawa (n = 1) and Dhangadhi (n = 1). The number of XDR-TB in Kathmandu correlates well with its high population.

3.3. Mutations identified in the *rpoB*, *katG*, *inhA*, *gyrA*, *gyrB* and *rrs* genes

Sequence analysis identified the most frequent mutations conferring Ser to Leu amino acid substitution at position 531 (Ser531Leu) in *rpoB* (12/13), Ser315Thr in *katG*

(12/13), Asp94Gly in *gyrA* (7/13), and a mutation from A to G at nucleotide position 1400 (A1400G) in *rrs* (9/13). Other mutations with lower rates were seen in *rpoB* (Asp516Val; 1/13), *inhA* regulatory region (C-15T; 1/13), *gyrA* (Ser91Pro; 1/13, Asp94Ala; 2/13, Asp94Asn; 1/13, Asp94His; 1/13, and Asp94Tyr; 1/13), and *rrs* (C1401T and G1483T; two each), while none had mutations in the quinolone resistance-determining region of *gyrB* (Table 2).

3.4. Spoligotyping and MLST

Among XDR-TB isolates, Spoligotyping revealed the predominance of Beijing family strains (9/13). In addition, 1 strain of CAS family, 2 strains of T family (T1 and T2) and 1 strain of undefined type were also identified. MLST confirmed 8 isolates with Beijing spoligotype belonged to modern types (Table 2).

3.5. Cluster analysis by VNTR

VNTR typing grouped the isolates into seven unique patterns and two clusters (Figure 2). Each cluster contained three isolates of the Beijing family. Among the clustered isolates, 86 and 103 in a cluster (cluster 1) had the same profile of drug resistance-associated mutations (*rpoB*-Ser531Leu, *katG*-Ser315Thr, *gyrA*-Asp94Gly, and *rrs*-C1401T), whereas 84 carried a distinct mutation in *rrs* (A1400G). Similarly, 118 and 161 in another cluster (cluster 2) had the same profile of drug resistance-associated mutations (*rpoB*-Ser531Leu, *katG*-Ser315Thr, *gyrA*-Asp94Gly, and *rrs*-A1400G) and 123 showed a distinct mutation pattern (C-15T at *inhA* regulatory region instead of *katG*-Ser315Thr for INH resistance, *gyrA*-Asp94Asn for FQ resistance, and *rrs*-G1483T for KAN/CAP resistance).

4. Discussion

In this study, we investigated drug resistance-associated mutations and genotypes of XDR-MTB isolates in Nepal. This study also raises concerns over the high proportion of pre-XDR-TB in Nepal. The high rate of pre-XDR-MTB isolates implied the inappropriate usage of drugs, especially FQs, including OFX. OFX is the most commonly prescribed antibiotic for respiratory tract infection in Nepal and this might lead to the emergence of pre-XDR-TB with resistance to OFX. As drug resistance in *M. tuberculosis* is due to the stepwise accumulation of mutations in the genome, this pool of pre-XDR-MTB isolates are always at the risk of developing XDR-TB.

Sequence analysis of the hot spot regions of various genetic loci showed that the most common mutations among XDR isolates were Ser531Leu of *rpoB*, Ser315Thr of

katG, Asp94Gly of *gyrA* and A1400G of *rrs* for RIF, INH, OFX and KAN/CAP resistance, respectively. Other studies have also reported similar mutations among XDR-TB isolates from different countries.^{20, 21, 22, 23} As mutations such conferring amino acid substitutions, Ser531Leu in *rpoB* and Ser315Thr in *katG* with low fitness costs are known to dominate the drug-resistant isolates.²⁴

Genotyping of the isolate by spoligotyping and MLST pointed out the predominance of strains belonging to the modern type Beijing genotypes. The similar involvement of XDR-MTB by modern type Beijing genotypes has been reported from South Africa,⁴ India,²⁰ and China,²³ while the ancient type Beijing family predominates in Japan.²⁵ Over-representation of Beijing genotype in XDR-MTB in this study compared to the lower prevalence of this genotype in non-MDR and MDR isolates (33 and 51 %, respectively; data not shown) supported the previous study that this genotype has been associated with drug resistance,^{4, 26} because of its higher mutation rates and lower fitness costs with specific mutations.²⁴ The significantly low average age of patients suffering from Beijing genotype MTB compared to patients suffering from MTB with other genotypes (23.1 ± 4.8 vs 39.5 ± 4.9 years old; Table 2) may suggest the higher transmissibility of Beijing genotype XDR-MTB among the young generation because of their frequent movement.²⁷

Although the numbers of isolates were small, complete matches of VNTR, including three hypervariable loci (QUB 11a, QUB 3232, QUB 3336) and drug resistance-associated mutations between two isolates in each cluster, suggested the possible transmission of XDR-TB in Nepal. MDR treatment of a patient who was the source of strain No. 103 started 3rd, April 2006 and the duration of MDR treatment was 12 month. In contrast, that of strain No. 86 started 29th, October 2009 and the duration of MDR treatment was 1 month. By these facts, we arrived at the idea that patient with strain No. 103 might be a source of transmission of XDR-TB and that with strain No. 86 might be a recipient. Alternatively, there might be common transmission source(s) to these patients. Situation was different in another cluster. MDR treatment of a patient who was the source of strain No. 118 started 23rd, September 2008 and the duration of MDR treatment was 2 month and primary XDR-TB was suspected. In contrast, that of strain No. 161 started 28th, January 2009 and the duration of MDR treatment was 14 month. The existence of common infection source of these strains was supposed. The transmission of XDR-TB was also speculated from the fact that three patients (from whom strain No. 84, 90 and 123 were isolated) were naive for MDR-TB treatment. It is

interesting that transmission of XDR-TB were speculated not only within Kathmandu but also between Kathmandu and Dhangadhi, apart more than 650 km (Figure 1). As Kathmandu is the capital of Nepal and people come and go frequently from different parts of Nepal, transmission between people living in Kathmandu and those living far from Kathmandu might be possible. Indeed, the patient from whom strain No. 161 was isolated has a history of traveling to Kathmandu. The possibility of transmission of XDR-TB seemed to be high, especially in cluster 1 (including strains No. 86 and 103), because the *rrs*-C1401T mutation carried by both strain No. 86 and 106 was rare between KAN/CAP-resistant isolates.^{10, 13} On the other hand, care should be taken when concluding XDR-TB transmission in cluster 2 (including strains No. 118 and 161) as both of the mutations, *gyrA*-Asp94Gly and *rrs*-A1400G, have been reported to be rather common in OFX- and KAN/CAP-resistant MTB, respectively, and the distance between the two cities is great. The high rate of pre-XDR-TB in MDR-TB might suggest the acquisition of XDR phenotype during successive transmission as these strains belong to the Beijing family, known to have higher mutation-acquiring capacity. The high number of MDR-TB patients who stop treatment in Nepal could also explain this high drug resistance acquisition rate.⁵ Both the possibility of direct transmission and acquired resistance should be considered equally for XDR-TB in Nepal.

5. Conclusion

The majority of XDR-MTB isolates in this study belonged to the Beijing family. Infections of this family were more common among younger generation than those belonging to other spoligotype families. In addition, the identical pattern of VNTR and drug resistance-associated mutations suggested the possible transmission of Beijing genotype XDR-MTB among people in Nepal. Our findings emphasize the urgent need to identify patients suffering from XDR-TB with Beijing genotype MTB and to treat them in isolated wards for a better control program to prevent the spread of this incurable disease.

Acknowledgements

We thank GENETUP National Reference Laboratory for giving us the opportunity to collect MDR and XDR-TB cases. We also thank Haruka Suzuki and Aiko Ohnuma for their technical support during the experiments.

This study was supported in part by J-GRID; the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (MEXT), the Global Center of Excellence (COE) Program, “Establishment of International Collaboration Centers for Zoonosis Control” from MEXT, a grant from U.S.-Japan Cooperative Medical Science Programs to Y. S., a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) to Y. S. and C. N., and a Grant-in-Aid for Research on Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour, and Welfare of Japan to Y. S.

Conflict of interest statements: All authors have no competing interests.

References

1. World Health Organization. **Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response**. Report no. 2010.WHO/HTM/TB/2010.3.
<http://www.who.int/tb/challenges/mdr/xdr/en/index.html>
2. Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell SK, Li X, Moll AP, Friedland G, Sturm AW, Gandhi NR. **Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa**. Emerg Infect Dis. 2011; 17:510–3.
3. Banerjee R, Schechter GF, Flood J, Porco TC. **Extensively drug-resistant tuberculosis: new strains, new challenges**. Expert Rev Anti Infect. Ther. 2008; 6:713–724.
4. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. **Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa**. Int J Tuberc Lung Dis. 2008; 12:99–104.
5. Malla P, Kanitz EE, Akhtar M, Falzon D, Feldmann K, Gunneberg C, Jha SS, Maharjan B, Prasai MK, Shrestha B, Verma SC, Zignol M. **Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006**. PLoS ONE. 2009; 4:e8313.
6. Poudel A, Nakajima C, Fukushima Y, Suzuki H, Pandey BD, Maharjan B, Suzuki Y. **Molecular characterization of multidrug-resistant *Mycobacterium tuberculosis* isolated in Nepal**. Antimicrob Agents Chemother. 2012; 56:2831-6.

7. Filliol I, Driscoll JR, Van Soolingen D, Kreiswirth BN, Kremer K, Valétudie G, Anh DD, Barlow R, Banerjee D, Bifani PJ, Brudey K, Cataldi A, Cooksey RC, Cousins DV, Dale JW, Dellagostin OA, Drobniewski F, Engelmann G, Ferdinand S, Gascoyne-Binzi D, Gordon M, Gutierrez MC, Haas WH, Heersma H, Källenius G, Kassa-Kelembho E, Koivula T, Ly HM, Makristathis A, Mammina C, Martin G, Moström P, Mokrousov I, Narbonne V, Narvskaya O, Nastasi A, Niobe-Eyangoh SN, Pape JW, Rasolofo-Razanamparany V, Ridell M, Rossetti ML, Stauffer F, Suffys PN, Takiff H, Texier-Maugein J, Vincent V, De Waard JH, Sola C, Rastogi N. **Global distribution of *Mycobacterium tuberculosis* spoligotypes.** Emerg Infect Dis. 2002; 8:1347–49.
8. Filliol I, Driscoll JR, van Soolingen D, Kreiswirth BN, Kremer K, Valétudie G, Dang DA, Barlow R, Banerjee D, Bifani PJ, Brudey K, Cataldi A, Cooksey RC, Cousins DV, Dale JW, Dellagostin OA, Drobniewski F, Engelmann G, Ferdinand S, Gascoyne-Binzi D, Gordon M, Gutierrez MC, Haas WH, Heersma H, Kassa-Kelembho E, Ho ML, Makristathis A, Mammina C, Martin G, Moström P, Mokrousov I, Narbonne V, Narvskaya O, Nastasi A, Niobe-Eyangoh SN, Pape JW, Rasolofo-Razanamparany V, Ridell M, Rossetti ML, Stauffer F, Suffys PN, Takiff H, Texier-Maugein J, Vincent V, de Waard JH, Sola C, Rastogi N. **Snapshot of moving and expanding clones of *Mycobacterium tuberculosis* and their global distribution assessed by spoligotyping in an international study.** J. Clin Microbiol. 2003; 41:1963–1970.
9. Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. **Worldwide occurrence of Beijing/W strains of *Mycobacterium tuberculosis*: a systematic review.** Emerg Infect Dis. 2002; 8:843–849.
10. Ramaswamy S, and Musser JM. **Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update.** Tuber Lung Dis. 1998; 79:3–29.
11. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. **Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*.** Lancet. 1993; 341:647-650.
12. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR Jr, Telenti A. **Cloning and nucleotide sequence of *Mycobacterium tuberculosis gyrA* and *gyrB* genes and detection of quinolone resistance mutations.** Antimicrob Agents Chemother. 1994; 38: 773–80.

13. Suzuki Y, Katsukawa C, Tamaru A, Abe C, Makino M, Mizuguchi Y, Taniguchi H. **Detection of kanamycin-resistant *Mycobacterium tuberculosis* by identifying mutations in the 16S rRNA gene.** J Clin Microbiol. 1998; 36:1220-5.
14. Maus CE, Plikaytis B B, and Shinnick TM. **Molecular analysis of cross resistance to capreomycin, kanamycin, amikacin, and viomycin in *Mycobacterium tuberculosis*.** Antimicrob Agents Chemother. 2005; 49:3192-3197.
15. World Health Organization. **Guidelines for surveillance of drug resistance in tuberculosis-4th ed.** 583 WHO/HTM/TB/2009.422. 2009. WHO, Geneva, Switzerland.
16. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. **Simultaneous detection and strain differentiation of mycobacterium tuberculosis for diagnosis and epidemiology.** J Clin Microbiol. 1997; 35:907–914.
17. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimuño L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, Garcia de Viedma D, Garzelli C, Gazzola L, Gomes HM, Guttierrez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ho ML, Martin C, Martin C, Mokrousov I, Narvskaja O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim Z, Rasolofo-Razanamparany V, Rasolonalavona T, Rossetti ML, Rüsch-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, Somoskovi A, Skuce RA, van Soolingen D, Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC, Warren RM, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. ***Mycobacterium tuberculosis* complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology.** BMC Microbiol. 2006; 6:23.
18. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Loch C. **Variable human minisatellite-like regions in the *Mycobacterium tuberculosis* genome.** Mol Microbiol. 2000; 36:762-771.
19. Filliol I, Motiwala AS, Cavatore M, Qi W, Hazbón MH, Bobadilla del Valle M, Fyfe J, García-García L, Rastogi N, Sola C, Zozio T, Guerrero MI, León CI, Crabtree J, Angiuoli S, Eisenach KD, Durmaz R, Joloba ML, Rendón A, Sifuentes-Osornio J, Ponce de León A, Cave MD, Fleischmann R, Whittam TS, Alland D. **Global phylogeny of *Mycobacterium tuberculosis* based on single nucleotide**

- polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set.** J Bacteriol. 2006; 188:759-72.
20. Ajbani K, Rodrigues C, Shenai S, Mehta A. **Mutation detection and accurate diagnosis of extensively drug resistant tuberculosis: report from a tertiary care center in India.** J Clin Microbiol. 2011; 49:1588–90.
 21. Ali A, Hasan R, Jabeen K, Jabeen N, Qadeer E, Hasan Z. **Characterization of mutations conferring extensive drug resistance to *Mycobacterium tuberculosis* isolates in Pakistan.** Antimicrob Agents Chemother. 2011; 55:5654-9.
 22. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H. **Emergence of extensively drug-resistant *Mycobacterium tuberculosis* clinical isolates from the Delhi Region in India.** Antimicrob Agents Chemother. 2010; 54:4789-93.
 23. Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Liu Y, Nie L, Guo A, Li C. **Characterization of extensively drug resistant *Mycobacterium tuberculosis* clinical isolates in China.** J Clin Microbiol. 2008; 46:4075–7.
 24. Gagneux S. **Fitness cost of drug resistance in *Mycobacterium tuberculosis*.** Clin Microbiol Infect. 2009; 15(Suppl 1):66-8.
 25. Murase Y, Maeda S, Yamada H, Ohkado A, Chikamatsu K, Mizuno K, Kato S, Mitarai S. **Clonal expansion of multidrug resistant and extensively drug resistant tuberculosis, Japan.** Emerg Infect Dis. 2010; 16:948-54.
 26. de Steenwinkel JE, Ten Kate MT, de Kneegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, Verbrugh HA, van Soolingen D, Bakker-Woudenberg IA. **Drug Susceptibility of *Mycobacterium tuberculosis* Beijing Genotype and Association with MDR TB.** Emerg Infect Dis. 2012; 18:660-3.
 27. Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, Borgdorff MW, Cobelens FG, van Soolingen D. **The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam.** Int J Tuberc Lung Dis. 2009; 13:900-6.

Figure Legends

Figure 1. Geographical location of XDR-TB isolation. Cities where XDR-MTB has been isolated are indicated by a closed circle.

Figure 2. Dendrogram and schematic representation of VNTR typing and spoligotyping results obtained with 13 XDR-TB isolates in Nepal. Column A: dendrogram (UPGMA method, distance matrix average of spoligotyping-based and VNTR) built with Bionumerics version 6, B: strain identification, C: 26 loci VNTR results, D: spoligotyping-based defined clades; E: spoligotyping international type, F: geographical location, G: MDR treatment start date and H: Duration of MDR treatment.

Poudel *et al.* Fig. 1

Table 1. Nucleotide sequence of primers used for PCR and sequencing.

Locus	Primer	Nucleotide sequence (5'-3')	Target region	Product size (bp)
<i>gyrA</i>	TB <i>gyrA</i> S	AGCGCAGCTACATCGACTATGCG	220-339	321
	TB <i>gyrA</i> AS	CTTCGGTGTACCTCATCGCCGCC		
<i>gyrB</i>	TB <i>gyrB</i> S	CGGCACGTAAGGCACGAGAG	1373-1770	398
	TB <i>gyrB</i> AS	GAACCGGAACAACAACGTCAAC		
<i>rrs</i>	TB <i>rrs</i> S	AGTCCCGCAACGAGCGCAACCC	1350 – 1550	665
	TB <i>rrs</i> AS	GATGCTCGCAACCACTATCCA		

Table 2: Antimicrobial susceptibility profile and mutation pattern of the different drug-target genes or regions among XDR isolates.

Strain No.	Drug susceptibility profile*							Mutation pattern in different drug-target genes or regions†						Spoligotype based clade with ST	Geographical location	age of patient
	RFP	INH	STR	EMB	OFX	KAN	CAP	<i>rpoB</i>	<i>katG</i>	<i>inhA</i> regulatory region	<i>gyrA</i>	<i>gyrB</i>	<i>rrs</i>			
84	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt [§]	Asp94Gly	wt	A1400G	Beijing (Modern)	Kathmandu	21
86	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Gly	wt	C1401T	Beijing (Modern)	Kathmandu	16
90	R	R	R	R	R	R	R	Asp516Val	Ser315Thr	wt	Ser91Pro	wt	A1400G	Beijing (Ancient)	Kathmandu	26
103	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Gly	wt	C1401T	Beijing (Modern)	Kathmandu	24
108	R	R	S	S	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Gly	wt	A1400G	CAS	Kathmandu	40
118	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Gly	wt	A1400G	Beijing (Modern)	Kathmandu	25
123	R	R	R	R	R	R	R	Ser531Leu	wt	C-15T	Asp94Asn	wt	G1483T	Beijing (Modern)	Kathmandu	21
139	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Ala	wt	A1400G	Beijing (Modern)	Pokhara	25
140	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Ala	wt	A1400G	T2	Pokhara	33
142	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Tyr	wt	G1483T	New	Pokhara	45
151	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94His	wt	A1400G	T1	Bhairahawa	40
155	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Gly	wt	A1400G	Beijing (Modern)	Butwal	18
161	R	R	R	R	R	R	R	Ser531Leu	Ser315Thr	wt	Asp94Gly	wt	A1400G	Beijing (Modern)	Dhangadhi	32

*INH, isoniazid; RFP, rifampicin; STR, streptomycin; EMB, ethambutol; OFX, ofloxacin; KAN, kanamycin; CAP, capreomycin; R, resistant; S, susceptible.

† Mutations in *rpoB*, *katG* and *gyrA* are presented as amino acid changes with codon position; mutations in *rrs* gene and *inhA* promoter region are presented as nucleotide changes with mutation position.

§ WT, wild type.